
    
      This will be done by integrating data and samples collected from patients undergoing standard
      of care treatment for high-grade B cell lymphoma

      Data will be integrated from

        1. Clinical risk factors from the International Prognostic Index (IPI)

        2. Up-front genomic subtype based on molecular profiling of diagnostic biopsy

        3. Serial ctDNA monitoring during treatment.

        4. Radiological response imaging
    
  